Clinical Trials Logo
NCT number NCT03496402
Study type Interventional
Source Institut Curie
Contact Gudrun SCHLEIERMACHER, MD
Phone +33(0)144324554
Email gudrun.schleiermacher@curie.fr
Status Not yet recruiting
Phase N/A
Start date April 12, 2018
Completion date April 1, 2026

Clinical Trial Summary

Methodology:

Prospective, multicentric, open, non-randomised, non-therapeutic, interventional study


Clinical Trial Description

To identify and characterise:

- meaningful molecular genetic alterations,

- meaningful immunological features of high risk childhood, adolescents and young adult cancers, at diagnosis, during patient treatment and follow-up (time dimension).


Study Design


Related Conditions & MeSH terms


See also
  Status Clinical Trial Phase
Recruiting NCT02530463 - Nivolumab and Ipilimumab With 5-azacitidine in Patients With Myelodysplastic Syndromes (MDS) Phase 2
Completed NCT00003270 - Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer Phase 2
Terminated NCT02469415 - Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS) Phase 2
Completed NCT00001637 - Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults Phase 2
Completed NCT00987480 - Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine Phase 2
Recruiting NCT02385110 - Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Phase 2
Recruiting NCT02910752 - CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation Phase 1/Phase 2
Recruiting NCT02668653 - Quizartinib With Standard of Care Chemotherapy and as Maintenance Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML) Phase 3
Withdrawn NCT02829840 - Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML) Phase 1/Phase 2
Recruiting NCT02409121 - A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers N/A
Recruiting NCT02458014 - Study of Blinatumomab in Patients With B-cell Lineage Acute Lymphocytic Leukemia With Positive Minimal Residual Disease Phase 2
Recruiting NCT02441803 - Allogeneic Hematopoietic Stem Cell Transplantation (AlloSCT) Initial Salvage Therapy for Induction Failure Acute Myeloid Leukemia (AML) Phase 2
Unknown status NCT02360930 - Vincristine PK and PD in the AYA Population Compared to Younger Children N/A
Active, not recruiting NCT01682226 - Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies Phase 2
Completed NCT01057290 - Studying Biomarkers in Cell Samples From Young Patients With Acute Myeloid Leukemia N/A
Active, not recruiting NCT01049854 - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant Phase 2
Active, not recruiting NCT01410344 - Allogeneic Transplant in HIV Patients (BMT CTN 0903) Phase 2
Completed NCT01357655 - Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) Phase 2
Completed NCT01438138 - Study to Predict Risk of Relapse in Bone Marrow Cell Samples From Younger Patients With Acute Myeloid Leukemia N/A
Completed NCT01419496 - Study of Proteins in Promoting Chemotherapy Resistance in Samples From Patients With Acute Myeloid Leukemia N/A